Price
No data yet.
Social Signal Score
Revenue
$395.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Oz Adler
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Beta
- 2.44
- Country
- IL
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -22.17
Financials
Revenue
$395.0K-20.7%Net Income
$-2.85MEBITDA
$447.0KFree Cash Flow
$-2.28MEPS (diluted)
$-70.21Shares Outstanding (diluted)
40.6K-98.3%Operating Expenses
$-176.0KCash & Debt
$4.59MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $856.0K | $-12.18M | $-882.64 |
| 2024 | $1.31M | $-6.28M | $-9.72 |
| 2023 | $2.88M | $-5.12M | $-112.95 |
| 2022 | $1.35M | $-2.59M | $-132.57 |
| 2021 | $1.07M | $-5.80M | $-659.52 |
| 2020 | $550.0K | $-3.51M | $0.00 |
| 2019 | $498.0K | $-5.36M | $0.00 |
| 2018 | $838.0K | $-8.52M | $0.00 |
| 2017 | $487.0K | $-6.24M | $0.00 |
| 2016 | $0.00 | $-1.99M | $0.00 |
| 2015 | $0.00 | $-2.53M | $0.00 |
| 2014 | $0.00 | $-1.85M | $0.00 |
| 2013 | $0.00 | $59.4K | $0.00 |
| 2012 | $0.00 | $-3.54M | $-7.47 |
Valuation
SPRChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-66.67%Social Signal Score
Mentions (11)
- Newsglobenewswire.com·13d ago·Neutral
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations The U.S. patent applications cover proprietary combinations of NeuroThera's PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders
View source ↗ - Newsthenewswire.com·33d ago·Negative
…blic ‑ health importance of advancing new treatment options for adult Tourette Syndrome TEL AVIV, Israel – TheNewswire - September 2, 2026 - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced that it is pursuing U.S. Food and Drug Administration (“FDA”) Orphan Drug Designa…
View source ↗ - Newsthenewswire.com·34d ago·Negative
…blic ‑ health importance of advancing new treatment options for adult Tourette Syndrome TEL AVIV, Israel – TheNewswire - September 2, 2026 - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced that it is pursuing U.S. Food and Drug Administration (“FDA”) Orphan Drug Designa…
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
… NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, continued advancement in participant enrollment for the clinical trial assessing NeuroThera's innovative SCI-210 …
View source ↗ - Newsthenewswire.com·38d ago·Neutral
… – – TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that, in accordance with special resolution of shareholders passed on January 8, 2026 (the “ Consolidation Resolution ”), the Company will be implementing a consolidation (the “ Consolidation ”) of the outstanding common shares in the capital of the Company (the “ Common Shares ”) on the basis of one ne…
View source ↗ - Newsthenewswire.com·40d ago·Neutral
…26 – TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has engaged Dr. Reuter Investor Relations (" Dr. Reuter ") to provide investor awareness and communications services across Germany and the broader European capital markets, effective September 1, 2026. Dr. Reuter is a recognized European investor relations and financial communications firm wi…
View source ↗ - Newsglobenewswire.com·41d ago·Neutral
SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board The addition of leading AI researcher further strengthens SciSparc's scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market
View source ↗ - Newsglobenewswire.com·43d ago·Negative
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical development considerations for psychedelic drugs, including MDMA
View source ↗ - Newsglobenewswire.com·49d ago·Neutral
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million SciSparc Invests C$2.7 million and holds approximately 44.6% of NeuroThera's issued and outstanding common shares following the financing
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
SciSparc's Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination TEL AVIV, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced that the Japanese Patent Office has granted the company a patent for NeuroTh
View source ↗ - Newsthenewswire.com·55d ago·Neutral
NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination Toronto, Ontario – TheNewswire - A ugust 12 , 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced that the Japanese Patent Office has granted the company a patent for its pharmacological combination titled “Compositions and Methods for Potentiating Derivatives of
View source ↗
Insider trading
Open-market buys and sells by SPRC officers and directors.
- Bought
- —
- Sold
- $5k
0 trades
1 trade
- Shrem Itschaksold
31 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SPRC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.